Literature DB >> 1451948

Role of infiltrating T cells for impaired glucose metabolism in pancreatic islets isolated from non-obese diabetic mice.

E Strandell1, S Sandler, C Boitard, D L Eizirik.   

Abstract

Pancreatic islets isolated from non-obese diabetic (NOD) mice, all of which have insulitis, exhibit an impaired glucose metabolism. In order to investigate the role of infiltrating lymphocytes for this altered metabolism, we injected 12- to 13-week-old female NOD mice with monoclonal antibodies directed against either the alpha beta-T cell receptor, CD4+ or CD8+ T cells. Control NOD mice were injected with normal rat IgG or with the vehicle (phosphate buffered saline) alone. Injection of the three different monoclonal antibodies markedly reduced the mononuclear cell infiltration. An intravenous glucose tolerance test showed no differences between the groups. Islet insulin release in response to glucose was similar in all groups. In contrast, islets isolated from the control NOD mice with insulitis showed a high basal (1.7 mmol/l glucose) glucose oxidation rate and a small increase in the glucose oxidation rate in response to a high glucose concentration (16.7 mmol/l glucose). The monoclonal antibodies counteracted the elevated basal glucose oxidation rate of the islets. Parallel studies of stimulated mononuclear cells suggested that the contribution of glucose oxidized by islet-infiltrating lymphocytes could only partially explain the observed alterations in NOD mouse islet metabolism. Culture of islets obtained from NOD mice in the presence of the cytokine interleukin-1 beta induced a similar pattern of glucose metabolism as seen earlier in IgG or phosphate-buffered saline treated control NOD mice. In conclusion, alterations in the glucose oxidation rates seem to be an early sign of disturbance in islets isolated from NOD mice. These early alterations in glucose metabolism can be reversed in vivo by monoclonal antibodies directed against effector lymphocytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451948     DOI: 10.1007/bf00401420

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  44 in total

1.  Interleukin 1 and tumor necrosis factor signal transduction mechanisms: potential targets for pharmacological control of inflammation.

Authors:  J Saklatvala; F Guesdon
Journal:  J Rheumatol Suppl       Date:  1992-01

Review 2.  Biochemical and molecular actions of interleukin-1 on pancreatic beta-cells.

Authors:  S Sandler; D L Eizirik; C Svensson; E Strandell; M Welsh; N Welsh
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

Review 3.  The NOD mouse as a model of type I diabetes.

Authors:  Y Tochino
Journal:  Crit Rev Immunol       Date:  1987       Impact factor: 2.214

4.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

5.  Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte.

Authors:  J H Helderman
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

6.  Interleukin-1 beta depletes insulin messenger ribonucleic acid and increases the heat shock protein hsp70 in mouse pancreatic islets without impairing the glucose metabolism.

Authors:  D L Eizirik; M Welsh; E Strandell; N Welsh; S Sandler
Journal:  Endocrinology       Date:  1990-11       Impact factor: 4.736

7.  Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus.

Authors:  E Strandell; D L Eizirik; S Sandler
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

8.  Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice.

Authors:  B J Miller; M C Appel; J J O'Neil; L S Wicker
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

9.  Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells.

Authors:  A Bendelac; C Carnaud; C Boitard; J F Bach
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice.

Authors:  C Boitard; R Yasunami; M Dardenne; J F Bach
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  4 in total

1.  Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.

Authors:  J P Palmer
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice.

Authors:  T Linn; K Schneider; B Göke; K Federlin
Journal:  Acta Diabetol       Date:  1996-03       Impact factor: 4.280

Review 3.  The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.

Authors:  Décio L Eizirik; Maikel L Colli; Fernanda Ortis
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

4.  Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming.

Authors:  Adrian Villalba; Silvia Rodriguez-Fernandez; David Perna-Barrull; Rosa-Maria Ampudia; Laia Gomez-Muñoz; Irma Pujol-Autonell; Eva Aguilera; Mireia Coma; Mary Cano-Sarabia; Federico Vázquez; Joan Verdaguer; Marta Vives-Pi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-13       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.